Pathopartitions - Philadelphia, Pennsylvania 19104

Pathopartitions is categorized under Commercial Biotechnical Research in Philadelphia, PA .

Business Name: Pathopartitions
Contact Person: Franz Fogt
Address: 3160 Chestnut St # 200, Philadelphia, Pennsylvania 19104
Phone Number: (610) 642-8768
Annual Revenue (USD): $50.000 to $99.999
Founding Year: 2012
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Commercial Biotechnical Research
SIC Code: 8731
NAICS Code: 541711
Share This Business:
Related Businesses: Oncovirx - Philadelphia, PA 19104
Intervir Therapeutics - Philadelphia, PA 19104
Diathera LLC - Philadelphia, PA 19104
Vibe Pharmaceuticals - Philadelphia, PA 19104
Biotech Studio LLC - Philadelphia, PA 19104
Aum Lifetech Inc - Philadelphia, PA 19104
Metamorphosis LLC - Philadelphia, PA 19104
Microbiota Therapeutics - Philadelphia, PA 19104
Penzymes LLC - Philadelphia, PA 19104
Navirx LLC - Philadelphia, PA 19104
Betaplus Radiopharmaceuticals LLC - Philadelphia, PA 19104
Lignamed LLC - Philadelphia, PA 19104
Pathonomics - Philadelphia, PA 19104
Amyndas Biotherapeutics LLC - Philadelphia, PA 19104
Skelegen - Philadelphia, PA 19104
Cartcentric Diagnostics - Philadelphia, PA 19104
Liquid Biotech - Philadelphia, PA 19104
Epigen Cardio LLC - Philadelphia, PA 19104
Vector Biosystems - Philadelphia, PA 19104

The company Pathopartitions provides B2B services in the form of Commercial Biotechnical Research from its single location in Pennsylvania. 1 to 4 employees work for Pathopartitions, and the business now earns $50.000 to $99.999 per annum.

Pathopartitions was launched in 2012 and is classified under SIC code and category 8731 , and NAICS number and grouping 541711 . To contact Pathopartitions, please call Franz Fogt with the phone number (610) 642-8768 or visit its single location at 3160 Chestnut St # 200 in Philadelphia, Pennsylvania 19104.

The location of the single location can also be found using the coordinates 39.953553,-75.18659. Read more details about this business on the webpage or follow the company’s social media accounts, on Twitter and on Facebook.